Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity). The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling. On growth hormone (GH) binding, forms homodimers and binds JAK2 via a box 1-containing domain. Binding to SOCS3 inhibits JAK2 activation, binding to CIS and SOCS2 inhibits STAT5 activation. On growth hormone binding, GHR is ubiquitinated, internalized, down-regulated and transported into a degradative or non-degradative pathway. Complexed to a substantial fraction of circulating GH. Expressed in normal and tumorous mammary tissues, being localized in epithelial and myoepithelial/spindle cell components and in the activated fibroblasts of desmoplastic tumor stroma. Isoform 1, isoform 2 and isoform 3 are found in both normal and tumorous mammary tissues, isoform 1 being the predominant isoform. Isoform 1, isoform 3, isoform 4 and isoform 5 are expressed in the CMT-U335 cell line. The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding. The box 1 motif is required for JAK interaction and/or activation. The extracellular domain is the ligand-binding domain representing the growth hormone-binding protein (GHBP). The ubiquitination-dependent endocytosis motif (UbE) is required for recruitment of the ubiquitin conjugation system on to the receptor and for its internalization. On GH binding, phosphorylated on tyrosine residues in the cytoplasmic domain by JAK2. On ligand binding, ubiquitinated on lysine residues in the cytoplasmic domain. This ubiquitination is not sufficient for GHR internalization (By similarity). Produced by exon 8 skipping resulting in a frameshift and introduction of a stopcodon at position 12 of exon 9. Produced by exon 7 skipping resulting in a frameshift and introduction of a stopcodon at position 619. Produced by the usage of alternative splice donor/acceptor sites resulting in the elimination of the greater part of exon 6 and the beginning of exon 7. Produced by the usage of alternative splice donor site resulting in the elimination of a part of exon 7 and the entire exon 8. Belongs to the type I cytokine receptor family. Type 1 subfamily.